Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

Conditions

• Non-Small Cell Lung Cancer

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Ivonescimab Injection — BIOLOGICAL
  Subject will receive ivonescimab and chemotherapy as an IV injection
• Pembrolizumab Injection — BIOLOGICAL
  Subject will receive pembrolizumab and chemotherapy as an IV injection

Study Details

This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival assessed by investigator. The key secondary endpoints include response and safety.

Key Dates

Start date

Oct 26, 2023

Status verified

Jan 2026

Primary completion

Dec 31, 2028

Completion

Dec 31, 2029

Study Design

Enrollment

1,600 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Arm A - Ivonescimab and chemotherapy
  Subject will receive ivonescimab and chemotherapy
• Active Comparator: Arm B - Pembrolizumab and chemotherapy
  Subject will receive pembrolizumab and chemotherapy

Primary Outcome Measure

Overall Survival (OS) [ Time Frame: approximately 4 years ]

Central Contacts

• Summit Clinical Trial Information
  1-833-256-0522
  [email protected]

Locations (76)

Find similar trials in Phoenix, AZ

Related Studies

• Harvesting Cells for Experimental Cancer Treatments
  Enrolling By Invitation · National Cancer Institute (NCI) · Bethesda, Maryland
• Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
  PHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey
• Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
  Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
• JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
  PHASE3 · Recruiting · University of Texas Southwestern Medical Center · La Jolla, California